Latest Nektar Therapeutics News & Updates

See the latest news and media coverage for Nektar. We track all announcements, press releases, and industry mentions in real time, all in one place.

Nektar Therapeutics (Nektar)

Biopharmaceutical company developing autoimmune and inflammatory therapies

nektar.com

Headquarters: San Francisco, United States
Founded year: 1990
Company type: Public company
Number of employees: 50–700

Last updated Today

Latest news about Nektar Therapeutics (Nektar)

In short: Nektar reported Q1 2026 financial results, raised $373.8M in a public offering, and progressed its rezpegaldesleukin Phase III trial program.

Company announcements

May 7 Nektar

Nektar Therapeutics reports Q1 2026 financial results

Cash reaches $731.6M. Revenue $10.9M, net loss $44.9M. Advances rezpegaldesleukin Phase 3 trials. Raises $373.8M in offering.

April 23 Nektar

Nektar Therapeutics closes $373.8 million public offering

The offering includes full exercise of underwriters' option for additional shares sold at $92.00 per share. Gross proceeds are approximately $373.8 million before expenses.

April 21 Nektar

Nektar Therapeutics prices upsized $325 million public offering

Sells 3,532,609 shares at $92 each. Proceeds fund R&D, clinical trials, manufacturing. Closes April 23, 2026.

April 20 Nektar

Nektar Therapeutics announces proposed $250M public offering

The offering includes common stock and pre-funded warrants, with an option for underwriters to buy additional shares. Proceeds will fund R&D, clinical trials, and manufacturing.

Media coverage

May 26 MSN

Russell 3000 Shuffle: Ocugen, Nektar slated to join among healthcare stocks; Nano-X to drop off

The semi-annual rebalancing of U.S. equities is officially underway after FTSE Russell unveiled its preliminary list of shifts for the broad-market Russell 3000 Index on...

May 20 The Globe and Mail

Nektar Therapeutics Q1 Earnings Call Highlights

Detailed price information for Nektar Therapeutics (NKTR-Q) from The Globe and Mail including charting and trades.

May 15 The Globe and Mail

Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares

Detailed price information for Cogent Biosciences Inc (COGT-Q) from The Globe and Mail including charting and trades.

May 13 Yahoo Finance

Assessing Nektar Therapeutics (NKTR) Valuation After Strong REZPEG Prospects And Recent Share Price Momentum

Context on Nektar Therapeutics (NKTR) Nektar Therapeutics (NKTR) has drawn fresh attention after a...

Never miss news about Nektar

Track Nektar and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Nektar competitors & trending companies

Browse news for competitors to Nektar and other trending companies.